top of page
Search

Semaglutide vs. Tirzepatide: Which GLP-1 Weight Loss Medication Is Right for You?

Writer: Johanna Galyen
Johanna Galyen
Jun 19
6 min read

Semaglutide and tirzepatide (GLP-1s) are changing how we approach obesity and type 2 diabetes. Unlike traditional appetite suppressants and the constant cycle of dieting and exercise, these medications work by mimicking the body’s natural hormones to help regulate hunger and metabolism.


Many people have seen significant, lasting weight loss and improvements in overall health. Beyond weight management, GLP-1s can help stabilize blood sugar, reduce cardiovascular risks, and enhance quality of life—making them a breakthrough for many patients.


But what exactly are these medications, and how do they compare?


Here's a quick tip from WebMD


GLP-1 stands for glucagon-like peptide 1, which is a hormone your small intestine makes. When blood sugar goes up, GLP-1 encourages your body to make more insulin to lower blood sugar. These drugs do the same thing.

Let’s take a closer look.


Semaglutide

Originally developed to treat diabetes, semaglutide was approved by the FDA in 2017. It was named Ozempic® and approved for the treatment of diabetes. Then, to obtain coverage for weight loss, the same medication was packaged as Wegovy®.


According to PubMed, semaglutide has 94% similarity to the glucagon-like peptide produced by the body. The close similarity is what makes it so effective.


Who should take this medicine?


It is for adults with a body mass index (BMI)

  • 30 kg/m2 or greater - which is considered obesity

  • 27 kg/m2 or greater - which is considered overweight

    • AND there must be one additional comorbid condition such as high blood pressure, Type 2 Diabetes Mellitus, heart disease, or diagnosed obstructive sleep apnea.


Semaglutide injection is injected weekly into the subcutaneous tissue. Once in the body, it does three things


  1. Slows gastric (stomach) emptying

  2. Enhances insulin secretion

  3. Reduces glucagon release from the liver


This combination allows the body to process the food much more slowly than it normally would, so the person feels fuller for longer and, in turn, eats less.


Tirzepatide

Similar to semaglutide in its creation, Tirzepatide contains semaglutide and adds a GIP (Glucose-dependent insulinotropic polypeptide). It was named Mounjaro® for the treatment of type 2 diabetes and, like semaglutide, received weight-loss approval, giving rise to Zepbound®.


This combination, affectionately called a "twincretin" or "double agonist", of a GLP-1 and GIP creates a two-fold approach to weight management. Just like semaglutide, it is administered as a once-weekly subcutaneous injection.


Who should take this medicine?


According to the FDA, it is for adults with a body mass index (BMI)

  • 30 kg/m2 or greater - which is considered obesity

  • 27 kg/m2 or greater - which is considered overweight

    • AND there must be one additional comorbid condition such as high blood pressure, Type 2 Diabetes Mellitus, heart disease, or diagnosed obstructive sleep apnea.


How it works

Once in the body, it does three things


  1. Slows gastric (stomach) emptying

  2. Enhances insulin secretion

  3. Reduces glucagon release from the liver


Because of the additional peptide, some patients report fewer side effects and greater weight loss compared with semaglutide.



Historical Note:

For all those who enjoy a bit of medical history, in 1932 the word "incretin" was used to describe hormones, specifically insulin, that help the body deal with the food that was eaten. Later in 1964, scientists published a paper noting that post-meal glucose levels were directly proportional to what people ate. Therefore, the term " the incretin effect " was coined. Although insulin is the most well-known hormone in glucose metabolism, the Incretin Effect specifically refers to GLP-1 and GIP.

The Results


  • Semaglutide showed an average of 15-19% weight loss

  • Tirzepatide showed an average of 15-22% weight loss


The results are similar, and (yes) tirzepatide does show a slight improvement in weight loss. Percentage weight loss can be confusing because it varies from person to person. To help explain this better, let's look at two different weight scenarios.


  • Patient A: 350 pounds - if they achieve 15% weight loss, they would lose 52.5 pounds with a new weight of 297.5 pounds

  • Patient B: 250 pounds - if they achieve a 15% weight loss, they would lose 37.5 pounds with a new weight of 212.5 pounds


As one can see, starting weight does make a difference in the total amount lost. However, the weight lost helps the body in ways that go beyond the number shown on the bathroom scale.


Other Benefits:

The benefits of GLP-1s are not merely limited to weight loss. According to an article by the American Heart Association, GLP-1s showed "significant reductions of major adverse cardiovascular events and additional cardiovascular outcomes, such as hospitalizations for heart failure." The article also says that the risk of clot-related events, such as heart attack, was reduced. - even though the patient already had conditions such as hardened arteries from plaque.


Of course, since semaglutide and tirzepatide were originally developed to treat Type 2 Diabetes Mellitus, it would be prudent to discuss how they improve insulin management. These medications help reduce blood sugar levels - fasting and post-meal. Hemoglobin A1c levels also come down. This can lead to requiring less insulin and reduce the harmful progression of diabetes that is seen in conditions such as chronic kidney disease and peripheral neuropathy.


What is the Financial $COST$


When considering medications, the financial aspect must also be considered in one's budget. Where one obtains the medication determines the cost for the patient. They can be obtained with a doctor's prescription, with insurance to help cover the cost, or at cash-based compounding pharmacies with the same prescription.


Brand-name medications GLP-1s, Wegovy and Zepbound, obviously come at a higher price, while compounded generics are cheaper.


The dose prescribed also heavily influences the final cost. All GLP-1s are started at a starting dose and gradually increased over several months to the maximum dose. The lower doses are significantly cheaper than the higher doses.


The Pharmacy Discussion

Brand-name medications come with known protections that pharmaceuticals provide - i.e., FDA-approved medication ingredients, safe suppliers, and the ability to avoid known allergens such as filler ingredients or dyes. These also come in pre-filled syringes to simplify dosing.


Generic GLP-1's are not created the same way Wegovy and Zepbound are. Semaglutide and Tirzepatide must be compounded by a compounding pharmacy. Consumers must understand that the FDA does not approve compounded semaglutide and Tirzeptadie.


Pharmacies, though, are still held accountable for the products they make and sell, and must obtain rigorous approvals to be accredited to sell compounded medications. When purchasing compounded medications, the buyer needs to be aware and ensure that the right product is made and prepared safely.


Some insurers cover semaglutide if you meet certain criteria, while others do not. And just because insurance covers it does not make it affordable, due to the co-pays and deductibles charged.


The cash-based option changes from pharmacy to pharmacy, and even from state to state. So each consumer must do their research.



Side effects and cautions

These medications are not without cautions and side effects.


Caution
Caution

The most common side effects include:

  • nausea

  • vomiting

  • bloating (gas and burping)

  • constipation

  • diarrhea.

Not everyone is a good candidate for GLP-1s

According to the FDA, those who must avoid GLP-1s

  • Medullary thyroid cancer, or even if a close family member has had this cancer, should not take it.

  • Multiple endocrine neoplasia syndrome type 2

  • History of acute or chronic pancreatitis

  • Pregnant women

  • Allergic to the ingredients


Additional Cautionary Note:

Since this medicine slows gastric emptying, those who struggle with gastroparesis must talk to their personal physician before starting this medication and weigh the pros and cons. While this is not a "boxed warning" from the FDA, it is a strong cautionary note that must be carefully addressed, as this can worsen this condition.


Also, people with acute pancreatitis or a history of pancreatitis should not start this medication without careful monitoring by their physician. GLP-1s can cause and worsen pancreatic inflammation, so it should not be taken carelessly.


Sudden weight loss can create an imbalance within the body. Because of this, those with a history of gallstones or diabetic retinopathy may experience worsening symptoms.


Lastly, these medications can worsen psychiatric symptoms. Those with mood disorders or those struggling with eating disorders such as anorexia nervosa or bulimia should engage with their psychiatrist and their medical provider before starting the injections.


Conclusion

When deciding between these, it is best to start by having a conversation with your healthcare provider to see whether either medication is right for you. Tirzepatide and Semaglutide are very popular and have demonstrated good weight loss. A thorough knowledge of the risks, benefits, and side effects should be carefully weighed before purchasing these medications.




Works Cited

Center. “Eli Lilly and Company - 716485 - 09/09/2025.” U.S. Food and Drug Administration, 2025, www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eli-lilly-and-company-716485-09092025.

Farzam, K., & Patel, P. (2024). Tirzepatide. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK585056/

Kommu, S., & Whitfield, P. (2024, February 11). Semaglutide. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK603723/

Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022). GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Circulation, 146(24), 1882–1894. https://doi.org/10.1161/circulationaha.122.059595

Min, T., & Bain, S. C. (2020). The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Therapy, 12(1). https://doi.org/10.1007/s13300-020-00981-0

Morgan, K. K. (2024, July 24). Mounjaro, Ozempic, Wegovy, Zepbound: What’s the Difference? WebMD; WebMD. https://www.webmd.com/obesity/mounjaro-ozempic-wegovy-zepbound-difference


 
 
 

Comments


bottom of page